{"id":343512,"date":"2026-11-11T10:49:39","date_gmt":"2026-11-11T05:19:39","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=343512"},"modified":"2026-11-11T10:49:39","modified_gmt":"2026-11-11T05:19:39","slug":"zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/","title":{"rendered":"Zydus Lifesciences Share Price: 25.7% CAGR in 3 Years as the Ahmedabad Drug Maker Tops Lupin"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#Zydus_Lifesciences_Share_Price_257_CAGR_in_3_Years_as_the_Ahmedabad_Drug_Maker_Tops_Lupin\" title=\"Zydus Lifesciences Share Price: 25.7% CAGR in 3 Years as the Ahmedabad Drug Maker Tops Lupin\">Zydus Lifesciences Share Price: 25.7% CAGR in 3 Years as the Ahmedabad Drug Maker Tops Lupin<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#How_Much_Has_the_Zydus_Lifesciences_Share_Price_Returned_in_3_Years\" title=\"How Much Has the Zydus Lifesciences Share Price Returned in 3 Years?\">How Much Has the Zydus Lifesciences Share Price Returned in 3 Years?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#Zydus_Lifesciences_vs_Lupin_and_Gland_Pharma_3-Year_CAGR_Compared\" title=\"Zydus Lifesciences vs Lupin and Gland Pharma: 3-Year CAGR Compared\">Zydus Lifesciences vs Lupin and Gland Pharma: 3-Year CAGR Compared<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#Valuation_and_Quality_Compared\" title=\"Valuation and Quality Compared\">Valuation and Quality Compared<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#What_Is_Driving_the_Zydus_Lifesciences_Stock\" title=\"What Is Driving the Zydus Lifesciences Stock?\">What Is Driving the Zydus Lifesciences Stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#How_the_Established_Players_Stack_Up\" title=\"How the Established Players Stack Up\">How the Established Players Stack Up<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#What_Should_Investors_Track_Next\" title=\"What Should Investors Track Next?\">What Should Investors Track Next?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#How_to_Compare_Pharma_Stocks_Yourself\" title=\"How to Compare Pharma Stocks Yourself\">How to Compare Pharma Stocks Yourself<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#A_Diversified_Drug_Maker_Trading_Below_Its_Sector_Multiple\" title=\"A Diversified Drug Maker Trading Below Its Sector Multiple\">A Diversified Drug Maker Trading Below Its Sector Multiple<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#What_is_the_Zydus_Lifesciences_share_price_today\" title=\"What is the Zydus Lifesciences share price today?\">What is the Zydus Lifesciences share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#What_is_the_3-year_CAGR_of_the_Zydus_Lifesciences_stock\" title=\"What is the 3-year CAGR of the Zydus Lifesciences stock?\">What is the 3-year CAGR of the Zydus Lifesciences stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#Is_Zydus_Lifesciences_better_than_Lupin\" title=\"Is Zydus Lifesciences better than Lupin?\">Is Zydus Lifesciences better than Lupin?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#What_does_Zydus_Lifesciences_do\" title=\"What does Zydus Lifesciences do?\">What does Zydus Lifesciences do?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#Is_the_Zydus_Lifesciences_stock_debt_free\" title=\"Is the Zydus Lifesciences stock debt free?\">Is the Zydus Lifesciences stock debt free?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#Is_Zydus_Lifesciences_expensive_compared_with_the_industry\" title=\"Is Zydus Lifesciences expensive compared with the industry?\">Is Zydus Lifesciences expensive compared with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#Which_pharma_stock_gave_the_highest_return_in_3_years\" title=\"Which pharma stock gave the highest return in 3 years?\">Which pharma stock gave the highest return in 3 years?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-3-year-cagr-vs-pharma-peers-lupin-gland-pharma\/#How_do_I_calculate_CAGR_for_a_stock\" title=\"How do I calculate CAGR for a stock?\">How do I calculate CAGR for a stock?<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h1><span class=\"ez-toc-section\" id=\"Zydus_Lifesciences_Share_Price_257_CAGR_in_3_Years_as_the_Ahmedabad_Drug_Maker_Tops_Lupin\"><\/span><strong>Zydus Lifesciences Share Price: 25.7% CAGR in 3 Years as the Ahmedabad Drug Maker Tops Lupin<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h1>\n<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Zydus Lifesciences previous close Rs 1,215.90. 3-year CAGR 25.7%. Up 2.0x since 9 Nov 2023. ROE 15.10%. Market cap Rs 1,21,002 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The <strong>Zydus Lifesciences share price<\/strong> closed at Rs 1,215.90 on 9 November 2026, a compounded annual return of 25.7% over three years. That compares with Lupin at 18.9% and Gland Pharma at 27.0%. The company has a market cap of Rs 1,21,002 crore and a P\/E of 28.13 against an industry P\/E of 40.13.<\/p>\n<\/p><\/div>\n<p>The <strong>Zydus Lifesciences share price<\/strong> has almost doubled in three years, and that has made Zydus Lifesciences one of the better performers among large Indian drug makers. The Ahmedabad-based company, earlier known as Cadila Healthcare, sells generic medicines, specialty drugs and vaccines.<\/p>\n<p>This article compares that run with Lupin and Gland Pharma. We calculate the three-year CAGR for all three and set the results beside market cap, valuation, return on equity and debt, using prices adjusted for corporate actions.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=zydus-lifesciences-share-price\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Much_Has_the_Zydus_Lifesciences_Share_Price_Returned_in_3_Years\"><\/span><strong>How Much Has the Zydus Lifesciences Share Price Returned in 3 Years?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Zydus Lifesciences stock closed at Rs 612.45 on 9 November 2023 and at Rs 1,215.90 on 9 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 1.99 lakh, which is a CAGR of 25.7%. This is a price return and leaves out dividends.<\/p>\n<p>CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Zydus Lifesciences can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.<\/p>\n<p>The <strong>Zydus Lifesciences share price<\/strong> has also been supported by a strong Indian prescription business, steady generic exports to the United States and a widening pipeline of complex products.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Zydus_Lifesciences_vs_Lupin_and_Gland_Pharma_3-Year_CAGR_Compared\"><\/span><strong>Zydus Lifesciences vs Lupin and Gland Pharma: 3-Year CAGR Compared<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table ranks the companies by three-year CAGR. Prices on 9 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 9 November 2026.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:14px 0;\">\n<tr>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Company<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Close on 9 Nov 2023<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Previous close (9 Nov 2026)<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Price multiple<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">3-year CAGR<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Gland Pharma<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,612.65<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 3,302.40<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">2.0x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">27.0%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Zydus Lifesciences<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 612.45<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,215.90<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">2.0x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">25.7%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Lupin<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,204.55<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 2,025.00<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">1.7x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">18.9%<\/td>\n<\/tr>\n<\/table>\n<p>The Zydus Lifesciences stock ranks second of the three at 25.7%. It sits ahead of Lupin (18.9%). The company ahead is Gland Pharma (27.0%). Gland Pharma finished slightly ahead of Zydus, with Lupin in third place. Zydus is the largest of the three by market cap, so its yearly return came on a bigger base of capital.<\/p>\n<p>Look at the <strong>Zydus Lifesciences share price<\/strong> alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_and_Quality_Compared\"><\/span><strong>Valuation and Quality Compared<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:14px 0;\">\n<tr>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Company<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Market cap<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">P\/E<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">ROE<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Debt to equity<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Zydus Lifesciences<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,21,002 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">28.13<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.13<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">15.10%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.50<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\"><a href=\"https:\/\/univest.in\/stocks\/lupin\/lupin-ltd-share-price-today\">Lupin<\/a><\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 92,007 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">17.62<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.13<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">21.65%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.26<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Gland Pharma<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 54,476 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">44.08<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.13<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">11.57%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.02<\/td>\n<\/tr>\n<\/table>\n<p>By market cap, Zydus Lifesciences is the largest of the group at Rs 1,21,002 crore, which gives it the scale advantage over Lupin, Gland Pharma. On earnings, Zydus Lifesciences shares trade at a P\/E of 28.13 against an industry P\/E of 40.13, a discount of about 30% to the sector, which leaves room if earnings keep growing. Peer multiples are Lupin at 17.62 and Gland Pharma at 44.08.<\/p>\n<p>Return on equity is 15.10% for the Zydus Lifesciences stock, which ranks second among the three, and debt to equity stands at 0.50. Trailing EPS is Rs 43.13. Diversified drug makers are valued on the breadth of their product baskets and the success of new launches, so the P\/E should be read next to return on equity and the debt position.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_Driving_the_Zydus_Lifesciences_Stock\"><\/span><strong>What Is Driving the Zydus Lifesciences Stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Zydus Lifesciences earns revenue from branded medicines in India, generic products in the United States and a growing set of specialty and biologic products. It also works on vaccines, and its research activity covers new chemical entities and complex generics.<\/p>\n<p>The company has expanded its presence in India through chronic therapy brands, which bring recurring prescriptions. Regulatory approvals for complex products abroad add to growth, although timing is uncertain.<\/p>\n<p>Followers of the <strong>Zydus Lifesciences share price<\/strong> usually track launches in the United States, growth of the India business, regulatory inspections and progress in specialty and biologic programmes.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_the_Established_Players_Stack_Up\"><\/span><strong>How the Established Players Stack Up<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Lupin is a Mumbai-based pharma company with strength in respiratory, cardiac and anti-infective medicines and a large export business. It compounded at 18.9% a year, on a market cap of Rs 92,007 crore and an ROE of 21.65%.<\/p>\n<p>Gland Pharma is a Hyderabad-based maker of injectable medicines that works with partners across regulated markets. It compounded at 27.0% a year, on a market cap of Rs 54,476 crore and an ROE of 11.57%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Should_Investors_Track_Next\"><\/span><strong>What Should Investors Track Next?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Three things are worth watching on the <strong>Zydus Lifesciences share price<\/strong>. First, new launches in the United States. Second, the growth of the India branded business. Third, progress in specialty and biologic products.<\/p>\n<p>At a P\/E of 28, the stock trades below the industry P\/E of 40, and its debt to equity of 0.50 is low. That leaves room if earnings keep growing.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live fundamentals of pharma stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Compare_Pharma_Stocks_Yourself\"><\/span><strong>How to Compare Pharma Stocks Yourself<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>You can repeat this exercise for any pair of stocks, including the Zydus Lifesciences stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P\/E against the industry P\/E, ROE and debt to equity. Benchmark the result against the <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> as well, so you know whether the stock beat the broader market.<\/p>\n<p>A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the <strong>Zydus Lifesciences share price<\/strong>, the same four checks give a more complete picture than price alone.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track the <strong>Zydus Lifesciences share price<\/strong> and compare pharma stocks live.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"A_Diversified_Drug_Maker_Trading_Below_Its_Sector_Multiple\"><\/span><strong>A Diversified Drug Maker Trading Below Its Sector Multiple<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Zydus Lifesciences share price<\/strong> compounded at 25.7% a year over three years, ahead of Lupin at 18.9% and behind Gland Pharma at 27.0%. Its P\/E of 28.13 is below the industry level.<\/p>\n<p>Lupin brings a higher ROE, while Gland Pharma brings an injectables focus and a smaller base. The choice depends on whether you prefer breadth or specialisation.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Zydus_Lifesciences_share_price_today\"><\/span><strong>What is the Zydus Lifesciences share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Zydus Lifesciences closed at Rs 1,215.90 on 9 November 2026, according to NSE data. It has a market cap of Rs 1,21,002 crore and a P\/E of 28.13. Check live quotes before acting, as prices change every trading day.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_3-year_CAGR_of_the_Zydus_Lifesciences_stock\"><\/span><strong>What is the 3-year CAGR of the Zydus Lifesciences stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Zydus Lifesciences delivered a price CAGR of 25.7% over three years, moving from Rs 612.45 on 9 November 2023 to Rs 1,215.90 on 9 November 2026. The figure excludes dividends and uses adjusted closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Zydus_Lifesciences_better_than_Lupin\"><\/span><strong>Is Zydus Lifesciences better than Lupin?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Zydus Lifesciences delivered a higher three-year CAGR at 25.7% than Lupin at 18.9%. Zydus is larger by market cap at Rs 1,21,002 crore against Rs 92,007 crore, while Lupin has a higher ROE at 21.65% against 15.10% and a lower P\/E of 17.62 against 28.13. The better choice depends on your view of each business.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Zydus_Lifesciences_do\"><\/span><strong>What does Zydus Lifesciences do?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Zydus Lifesciences, earlier known as Cadila Healthcare, is an Ahmedabad-based drug maker with generic, specialty and vaccine businesses in India and abroad.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_the_Zydus_Lifesciences_stock_debt_free\"><\/span><strong>Is the Zydus Lifesciences stock debt free?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The debt to equity ratio of the Zydus Lifesciences stock is 0.50 and its return on equity is 15.10%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Zydus_Lifesciences_expensive_compared_with_the_industry\"><\/span><strong>Is Zydus Lifesciences expensive compared with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Zydus Lifesciences trades at a P\/E of 28.13 against an industry P\/E of 40.13. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_pharma_stock_gave_the_highest_return_in_3_years\"><\/span><strong>Which pharma stock gave the highest return in 3 years?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Among the companies compared here, Gland Pharma delivered the highest three-year CAGR at 27.0%, followed by Zydus Lifesciences at 25.7%. Past returns do not guarantee future performance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_do_I_calculate_CAGR_for_a_stock\"><\/span><strong>How do I calculate CAGR for a stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Zydus Lifesciences share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Zydus Lifesciences closed at Rs 1,215.90 on 9 November 2026, according to NSE data. It has a market cap of Rs 1,21,002 crore and a P\/E of 28.13. Check live quotes before acting, as prices change every trading day.\"}},{\"@type\":\"Question\",\"name\":\"What is the 3-year CAGR of the Zydus Lifesciences stock?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Zydus Lifesciences delivered a price CAGR of 25.7% over three years, moving from Rs 612.45 on 9 November 2023 to Rs 1,215.90 on 9 November 2026. The figure excludes dividends and uses adjusted closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Is Zydus Lifesciences better than Lupin?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Zydus Lifesciences delivered a higher three-year CAGR at 25.7% than Lupin at 18.9%. Zydus is larger by market cap at Rs 1,21,002 crore against Rs 92,007 crore, while Lupin has a higher ROE at 21.65% against 15.10% and a lower P\/E of 17.62 against 28.13. The better choice depends on your view of each business.\"}},{\"@type\":\"Question\",\"name\":\"What does Zydus Lifesciences do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Zydus Lifesciences, earlier known as Cadila Healthcare, is an Ahmedabad-based drug maker with generic, specialty and vaccine businesses in India and abroad.\"}},{\"@type\":\"Question\",\"name\":\"Is the Zydus Lifesciences stock debt free?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The debt to equity ratio of the Zydus Lifesciences stock is 0.50 and its return on equity is 15.10%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.\"}},{\"@type\":\"Question\",\"name\":\"Is Zydus Lifesciences expensive compared with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Zydus Lifesciences trades at a P\/E of 28.13 against an industry P\/E of 40.13. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.\"}},{\"@type\":\"Question\",\"name\":\"Which pharma stock gave the highest return in 3 years?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Among the companies compared here, Gland Pharma delivered the highest three-year CAGR at 27.0%, followed by Zydus Lifesciences at 25.7%. Past returns do not guarantee future performance.\"}},{\"@type\":\"Question\",\"name\":\"How do I calculate CAGR for a stock?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zydus Lifesciences share price compounded at 25.7% a year over 3 years. See how it compares with Lupin and Gland Pharma on returns, valuation and ROE.<\/p>\n","protected":false},"author":38,"featured_media":343511,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[21931,17044,21930,21929],"class_list":["post-343512","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-pharma-stocks-india-3-year-return","tag-zydus-lifesciences-share-price","tag-zydus-lifesciences-stock","tag-zydus-vs-lupin"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["343511"],"rank_math_title":["Zydus Lifesciences Share Price: 25.7% CAGR vs Lupin"],"rank_math_description":["Zydus Lifesciences share price compounded at 25.7% a year over 3 years. See how it compares with Lupin and Gland Pharma on returns, valuation and ROE."],"rank_math_focus_keyword":["Zydus Lifesciences share price | Density Target: 1.2-1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/zydus-lifesciences-share-price-25-7-cagr-in-3-years-as-the-ahmedabad-drug-maker.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/343512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=343512"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/343512\/revisions"}],"predecessor-version":[{"id":343513,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/343512\/revisions\/343513"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/343511"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=343512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=343512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=343512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}